Literature DB >> 8925855

Reproducibility of technetium-99m mercaptoacetyltriglycine clearance.

A Piepsz1, M Tondeur, J Kinthaert, H R Ham.   

Abstract

The aim of this paper was to determine the reproducibility (precision) of technetium-99m mercaptoacetyltriglycine (MAG3) clearance and to compare it with that of chromium-51 ethylenediamine tetra-acetic acid (EDTA). Twelve young volunteers (aged between 21 and 34 years), without any history of medical problems, were enrolled in this study. The test was performed twice, at an interval of 8 days and under similar physiological conditions. After the intravenous injection of both tracers, 15 blood samples were taken between 3 and 240 min. A biexponential fit was adapted to the plasma disappearance curves (5- to 120-min samples for 99mTc-MAG3 and 10- to 240-min samples for 51Cr-EDTA); the clearances were calculated according to Sapirstein and corrected for body surface area. The mean clearance values were 110 (range 85-130) and 226 (range 109-319)ml/min/1.73 m2, respectively, for 51Cr-EDTA and 99mTc-MAG3. For 51Cr-EDTA clearance, the mean difference between the first and the second measurement was -2.1% of the mean of the two successive values (SD: 8.4%). In ten cases, the difference was less than 12%; in two cases, the differences were 15% and 18%, respectively. For 99mTc-MAG3 clearance, the mean difference between the first and the second measurement was -20% of the mean of the two successive values (SD: 25%). In six cases, the difference was less than 12%; in four cases, between 15% and 40%; and in two cases, more than 60%. Methodological factors (impurities contained in the commercial kit, variable protein binding) as well as physiological factors (pH of urine, sodium load, stress) may explain the lack of precision of the 99mTc-MAG3 clearance. It is concluded that changes in 99mTc-MAG3 plasma clearance should be interpreted with care in daily routine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8925855     DOI: 10.1007/bf01731844

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  16 in total

Review 1.  Measurement of renal function with radionuclides.

Authors:  C D Russell; E V Dubovsky
Journal:  J Nucl Med       Date:  1989-12       Impact factor: 10.057

2.  Selection of routine method for determination of glomerular filtration rate in adult patients.

Authors:  J Bröchner-Mortensen; P Rödbro
Journal:  Scand J Clin Lab Invest       Date:  1976-01       Impact factor: 1.713

3.  Quantitation of renal function using MAG3.

Authors:  C D Russell; E V Dubovsky
Journal:  J Nucl Med       Date:  1991-11       Impact factor: 10.057

4.  Studies in renal circulation during periods of life stress and accompanying emotional reactions in subjects with and without essential hypertension; observations on the role of neural activity in regulation of renal blood flow.

Authors:  J B PFEIFFER; H G WOLFF; O S WINTER
Journal:  J Clin Invest       Date:  1950-09       Impact factor: 14.808

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Determination of the technetium-99m mercaptoacetyltriglycine plasma clearance in children by means of a single blood sample: a multicentre study. The Paediatric Task Group of the EANM.

Authors:  A Piepsz; I Gordon; K Hahn; J Kolinska; J Kotzerke; R Sixt
Journal:  Eur J Nucl Med       Date:  1993-03

7.  The simultaneous determination in children of glomerular filtration rate and effective renal plasma flow by the single injection celarance technique.

Authors:  A Donath
Journal:  Acta Paediatr Scand       Date:  1971-09

8.  Renal clearance determination with one blood sample: improved accuracy and universal applicability by a new calculation principle.

Authors:  B Bubeck
Journal:  Semin Nucl Med       Date:  1993-01       Impact factor: 4.446

Review 9.  Technetium-99m (99mTc) mercaptoacetyltriglycine: update on the new 99mTc renal tubular function agent.

Authors:  D Eshima; A Taylor
Journal:  Semin Nucl Med       Date:  1992-04       Impact factor: 4.446

10.  Precision of single injection (51Cr)EDTA plasma clearance and endogenous creatinine clearance determinations in children.

Authors:  J Brochner-Mortensen; K Rohbrandt; R B Lauritzen
Journal:  Scand J Clin Lab Invest       Date:  1977-11       Impact factor: 1.713

View more
  6 in total

1.  Angiotensin-converting enzyme inhibitor-enhanced MR renography: repeated measures of GFR and RPF in hypertensive patients.

Authors:  Jeff L Zhang; Henry Rusinek; Louisa Bokacheva; Ruth P Lim; Qun Chen; Pippa Storey; Keyma Prince; Elizabeth M Hecht; Danny C Kim; Vivian S Lee
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-21

2.  Monitoring renal function: a prospective study comparing camera-based technetium-99m mercaptoacetyltriglycine clearance and creatinine clearance.

Authors:  Raghuveer Halkar; Andrew Taylor; Amita Manatunga; Muta M Issa; Samuel E Myrick; Sandra Grant; Neeta V Shenvi
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

3.  Maturation of malfunctioning kidneys.

Authors:  Evelyn Vranken; Hamphrey Ham; Khalid Ismaili; Michelle Hall; Frank Collier; Rudi A Dierckx; Amy Piepsz
Journal:  Pediatr Nephrol       Date:  2005-06-24       Impact factor: 3.714

4.  (99m)Tc(CO)3(NTA): a (99m)Tc renal tracer with pharmacokinetic properties comparable to those of (131)I-OIH in healthy volunteers.

Authors:  Andrew T Taylor; Malgorzata Lipowska; Luigi G Marzilli
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

5.  99mTc(CO)3(NTA) and 131I-OIH: comparable plasma clearances in patients with chronic kidney disease.

Authors:  Andrew T Taylor; Malgorzata Lipowska; Hui Cai
Journal:  J Nucl Med       Date:  2013-02-19       Impact factor: 10.057

6.  Initial Evaluation of (99m)Tc(CO)3(ASMA) as a Renal Tracer in Healthy Human Volunteers.

Authors:  Malgorzata Lipowska; Jeffrey Klenc; Russell D Folks; Andrew T Taylor
Journal:  Nucl Med Mol Imaging       Date:  2014-05-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.